Vonova
Developing a minimally invasive endovascular platform for brain access and treatment of neurological conditions.
Website: https://www.vonova.io/
Cover Block
Public sources
| Attribute | Details |
|---|---|
| Company | Vonova |
| Tagline | Developing a minimally invasive endovascular platform for brain access and treatment of neurological conditions. [vonova.io, retrieved 2024] |
| Headquarters | San Diego, United States [vonova.io, retrieved 2024] |
| Founded | 2019 [vonova.io, retrieved 2024] |
| Stage | Seed [SmartGateVC, September 2024] |
| Business Model | Hardware + Software [vonova.io, retrieved 2024] |
| Industry | Healthtech [SmartGateVC, September 2024] |
| Technology | Biotech / Life Sciences [vonova.io, retrieved 2024] |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) [vonova.io, retrieved 2024] |
| Funding Label | Seed (total disclosed ~$1,000,000) [SmartGateVC, September 2024] |
Links
Public sources
- Website: https://www.vonova.io/
- LinkedIn: https://www.linkedin.com/company/vonovaneuro
Independently corroborated -- Confirmed by company website and LinkedIn page.
Executive Summary
Public sources Vonova is developing a catheter-based platform to access the brain's surface through its blood vessels, a technical approach that, if proven, could shift the standard of care for a range of neurological interventions away from open skull surgery. The company's immediate focus is on evacuating chronic subdural hematomas (cSDH), a condition affecting primarily elderly patients where fluid collects between the brain and its outer lining, representing a reported $1.6 billion market [SmartGateVC, September 2024]. Founded in 2019 by a medical device engineer and a neurointerventional surgeon, the venture has progressed to preclinical testing for its Cerebro Clear system [Med-Tech World, June 2025] and secured initial seed capital from a syndicate including SmartGateVC, XEIA, and Device of Tomorrow Capital [NeuroTech Harbor, June 2025].
The founding team pairs Wesley Jones, a CEO with a decade of experience developing cardiac devices for firms like Medtronic, with Dr. José Morales, the device's inventor and a practicing neurointerventional surgeon at an academic medical center [vonova.io, retrieved 2024]. This combination of engineering iteration and clinical insight is central to the company's technical risk profile. The business model is hardware-driven, with the Cerebro platform intended for sale to hospitals, though revenue generation remains pre-commercial. Over the next 12-18 months, the critical milestones for investors to track will be the initiation of first-in-human clinical studies, the securing of regulatory designations like the FDA's Breakthrough Device, and the articulation of a clear path beyond the initial cSDH indication into broader neurological applications.
Lightly corroborated -- Core claims (team, funding, product focus) are corroborated by multiple independent sources, but key operational milestones like preclinical completion are reported by a single trade publication.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | Hardware + Software |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | Seed (total disclosed ~$1,000,000) |
How the Company Got Here
Public sources
Vonova was founded in 2019 in San Diego, California, with the goal of developing a new platform for brain access [Crunchbase]. The company's origin story centers on the collaboration between its two co-founders: Wesley Jones, a medical device engineer, and Dr. José Morales, a neurointerventional surgeon and the device's chief inventor [vonova.io, ORCID]. The public narrative frames this as a classic medtech pairing, combining engineering development experience with clinical expertise to address a complex anatomical challenge.
The company's primary public milestone is its seed financing, which was structured as a convertible note of up to $1 million led by SmartGateVC and closed in September 2024 [SmartGateVC, September 2024]. This was followed by subsequent announcements in June 2025 of seed funding from a syndicate that included XEIA and Device of Tomorrow Capital [Med-Tech World, June 2025]. The company has also received non-dilutive support through the NIH Blueprint MedTech program, administered with NeuroTech Harbor [NeuroTech Harbor, June 2025]. By mid-2025, the company reported completing preclinical testing for its initial product, the Cerebro Clear system [Med-Tech World, June 2025].
Lightly corroborated -- Core facts like founding year and location are confirmed by Crunchbase and the company website. Funding events are reported by investor and trade press, but the total capitalization and precise entity structure are not independently verified from public filings.
Product and Technology
Sources and analysis The company's core product is the Cerebro platform, a catheter-based neurovascular system designed to access the brain's surface through the vascular system, a method that could potentially avoid the need for open craniotomy or skull drilling [vonova.io, retrieved 2024]. The system is guided by real-time imaging, a common requirement for endovascular navigation, though the specific imaging modality is not detailed in public materials.
Vonova's initial clinical target is the evacuation of chronic subdural hematoma (cSDH) with a specific iteration called Cerebro Clear [SmartGateVC, September 2024]. The company reported completing preclinical testing for this application in mid-2025 [Med-Tech World, June 2025]. Earlier public positioning also referenced a broader Cerebro Atlas System intended for applications like epilepsy surgery and brain-computer interfaces, but recent investor communications have centered on the cSDH pathway [LinkedIn, retrieved 2024] [SmartGateVC, September 2024].
Lightly corroborated -- Product claims are primarily company-sourced; the preclinical milestone and cSDH focus are corroborated by an independent publisher.
Where the Demand Sits
Public sources The company's seed-stage bet rests on the premise that a specific, high-procedure-volume neurological condition is underserved by existing surgical methods, creating a clear entry point for a new access technology.
Chronic subdural hematoma (cSDH), the initial clinical target for Vonova's Cerebro Clear system, represents a substantial and growing procedural market. The sole cited market sizing claim, from investor SmartGateVC, values the cSDH market at $1.6 billion [SmartGateVC, September 2024]. While this figure is not independently verified by a third-party research firm, it provides a directional anchor for the opportunity. The condition primarily affects the elderly, a demographic that is expanding globally and is particularly vulnerable to falls and anticoagulant use, both key risk factors for cSDH. This demographic tailwind suggests a durable, if not expanding, patient population requiring intervention.
Demand is driven by the clinical limitations of the current standard of care. Traditional treatment involves a surgical procedure known as a burr hole craniotomy, which requires drilling through the skull. This approach, while effective, carries inherent risks associated with open brain surgery, including infection, bleeding, and longer recovery times, which are particularly consequential for older patients [Med-Tech World, June 2025]. The clinical wedge for a minimally invasive alternative is therefore clear: a system that can evacuate the hematoma through the vascular system without skull penetration addresses a documented unmet need for a safer, less traumatic procedure. The company's positioning suggests its platform technology could later be applied to adjacent neurological markets, such as epilepsy monitoring or therapeutic delivery, though these remain longer-term horizons not substantiated by current public traction.
Regulatory and reimbursement pathways will be a primary macro force shaping market adoption. As a novel Class III medical device, the Cerebro Clear system will require a Premarket Approval (PMA) from the U.S. Food and Drug Administration, a process that demands robust clinical data to demonstrate safety and effectiveness. Success in this arena is non-negotiable for market entry. Furthermore, securing favorable CPT codes and reimbursement rates from Medicare and private insurers will be critical for commercial viability, as cSDH procedures are frequently performed on the Medicare population. The company's participation in the NIH Blueprint MedTech program provides non-dilutive support and strategic guidance, which may aid in navigating these complex regulatory and reimbursement landscapes [NeuroTech Harbor, June 2025].
Chronic Subdural Hematoma (cSDH) Market | 1.6 | $B
The single, investor-cited figure frames the immediate addressable market, though investors should treat it as a bullish estimate until corroborated by independent analyst reports.
Lightly corroborated -- Market size is a single, unverified investor claim. Demographic and clinical demand drivers are supported by general medical literature and reported product positioning.
Competitive Landscape
Sources and analysis Vonova's competitive position is defined by its pursuit of a fundamentally different anatomical pathway to the brain, a bet that places it against both established surgical incumbents and a small field of emerging neurovascular access specialists.
The available research, however, does not identify specific, named commercial entities developing analogous catheter-based brain surface access platforms. The competitive analysis must therefore proceed without a direct, head-to-head feature comparison.
The competitive map for treating chronic subdural hematoma (cSDH), Vonova's stated initial indication, is bifurcated. On one side are the entrenched surgical standards: burr-hole craniostomy and craniotomy, which are performed by neurosurgeons using tools from large medical device conglomerates. These are the default procedures, supported by decades of clinical practice and a vast, established supply chain. On the other side are a handful of emerging minimally invasive techniques. These include twist-drill craniostomy and, more relevantly, evolving endovascular approaches. While no direct commercial peer was named, the space for novel cSDH evacuation is active; for example, companies like CereVasc are developing transvenous embolization systems for different neurological conditions, illustrating investor interest in alternative vascular routes [SmartGateVC, September 2024]. Adjacent substitutes also exist in the form of pharmaceutical therapies aimed at reducing recurrence rates, though these address a different part of the clinical problem.
Vonova's claimed edge rests on the proprietary design of its Cerebro platform and the specialized experience of its founding team. The technical differentiator is the attempt to create a stable, navigable conduit to the brain's surface entirely via the vascular system, ostensibly avoiding bone disruption. This is a hardware and procedural innovation. Defensibility, at this stage, is tied to intellectual property around the catheter and deployment mechanism and the deep clinical insight of co-founder Dr. José Morales, a practicing neurointerventional surgeon [ORCID]. This edge is durable only if the team can translate the prototype into a clinically validated device and secure robust patents before others attempt similar approaches. The non-dilutive support from the NIH Blueprint MedTech program provides a form of regulatory and development expertise that acts as a temporary moat, de-risking the path to first-in-human trials [NeuroTech Harbor, June 2025].
The company's most significant exposure is its late-mover disadvantage in a clinical setting dominated by simple, low-cost mechanical procedures. Neurosurgeons are highly trained in existing techniques, and hospital purchasing committees are notoriously resistant to adopting expensive new capital equipment without overwhelming evidence of superior outcomes or cost savings. A named competitor with an advantage would be any established player in the neurovascular space (e.g., Medtronic, Stryker) that decides to acquire or internally develop a similar endovascular access tool. Their existing commercial relationships with hospitals and massive clinical trial resources would present an almost insurmountable barrier for a seed-stage startup. Furthermore, Vonova has no visible ownership of a direct sales channel or proven reimbursement strategy, a critical gap that must be filled long before commercial launch.
The most plausible 18-month scenario hinges on clinical data. If Vonova successfully initiates and publishes positive early feasibility study results for Cerebro Clear, it would validate the core technical premise and likely attract a strategic partner or a larger Series A round to fund a pivotal trial. In this case, Vonova becomes the winner if it demonstrates clear procedural safety and a reduction in hospital length of stay compared to standard care. Conversely, it becomes the loser if technical hurdles in preclinical or early clinical testing prove intractable,such as an inability to reliably navigate the delicate vasculature or achieve complete hematoma evacuation,or if a well-funded competitor publicly unveils a similar system with more advanced clinical progress. The next phase is less about commercial competition and more about winning the race to clinical proof-of-concept.
Lightly corroborated -- The analysis of the broader treatment landscape and surgical incumbents is well-established. The assessment of Vonova's specific technical approach and team edge relies on company claims and founder profiles, which lack independent technical verification. No direct competitors were identified in sources.
Opportunity
Public sources A minimally invasive, catheter-based platform for brain access could unlock a multi-billion-dollar market by enabling new treatments for a range of neurological conditions without open surgery.
The headline opportunity for Vonova is to establish its Cerebro platform as the foundational access technology for endovascular neurosurgery. The evidence supporting this outcome is not yet clinical, but it is rooted in a clear and persistent market need. Chronic subdural hematoma (cSDH), the company's initial target, represents a $1.6 billion market where current treatments often involve invasive burr-hole surgery with significant risks for an elderly patient population [SmartGateVC, September 2024]. If Cerebro Clear can demonstrate safe and effective evacuation via the vascular system, it would address a specific, high-volume procedural gap. More significantly, a successful launch in cSDH would validate the core technical premise of navigating to the brain surface through blood vessels, creating a beachhead from which to expand into adjacent, higher-value indications like epilepsy monitoring or therapeutic delivery, which the company's earlier positioning referenced [vonova.io]. The platform's potential lies in converting a complex surgical access problem into a standardized, catheter-based procedure.
Vonova's path to scale hinges on executing a clear sequence of clinical and commercial milestones. The following scenarios outline plausible routes from initial product clearance to a category-defining platform.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Dominant cSDH Standard | Cerebro Clear becomes the preferred first-line intervention for chronic subdural hematoma in major neurovascular centers. | Successful FDA clearance and publication of pivotal trial data showing superior patient outcomes versus burr-hole surgery. | The $1.6 billion cSDH market is served by established but invasive techniques; a minimally invasive alternative with a compelling safety profile could rapidly gain adoption, as seen in other vascular specialties [SmartGateVC, September 2024]. |
| Platform Expansion into Epilepsy | The company leverages its vascular access to deploy next-generation, high-resolution cortical grids for seizure localization, displacing subdural strip electrodes placed via craniotomy. | Partnership with a leading neuromodulation company or epilepsy center to co-develop a diagnostic system. | The founding team's early materials emphasized applications in epilepsy and brain-computer interfaces, indicating technical feasibility for this direction [vonova.io]. The clinical advisor working with the team since 2020 could provide critical early clinical feedback [vonova.io]. |
Compounding for Vonova would manifest as a clinical data and procedural expertise moat. Each successful Cerebro procedure generates imaging data and surgeon feedback on navigation, which can refine the system's algorithms and improve ease-of-use. This creates a learning curve advantage over any new entrant. Furthermore, as neurosurgeons and neurointerventionalists are trained on the Cerebro platform for cSDH, the same physician cohort and hospital purchasing channels would be primed for adoption of future modules for other indications, lowering the commercial cost of expansion. The company's engagement with the NIH Blueprint MedTech program, which provides expert consultation and commercialization support, is an early signal of building this institutional knowledge base [NeuroTech Harbor, June 2025].
The size of the win, should the platform expansion scenario materialize, is anchored by the valuation of public medtech companies in adjacent spaces. For a relevant, though not direct, comparable, NeuroPace (NASDAQ: NPCE), a company focused on an implantable device for responsive neurostimulation to treat epilepsy, currently holds a market capitalization of approximately $300 million. A platform that enables both therapeutic delivery (like hematoma evacuation) and advanced neural recording for diagnostics could command a significant premium by addressing multiple large neurological markets. If Vonova captured a meaningful portion of the cSDH market and demonstrated a viable path into epilepsy diagnostics, a valuation in the high hundreds of millions to low billions is a plausible outcome (scenario, not a forecast). This potential justifies the high-risk, high-reward profile of the seed-stage investment.
Lightly corroborated -- The core market size and platform expansion thesis are supported by investor and company materials, but clinical validation and commercial traction remain unproven.
Sources
Public sources
[vonova.io, retrieved 2024] Vonova | https://www.vonova.io/
[SmartGateVC, September 2024] SmartGateVC announces investment in Vonova, a pioneer in catheter-based brain interface technology | https://www.smartgate.vc/post/smartgatevc-announces-investment-in-vonova-a-pioneer-in-catheter-based-brain-interface-technology
[Med-Tech World, June 2025] Vonova Raises Funds for Brain Access Tech | https://med-tech.world/news/vonova-brain-access-tech-funding/
[NeuroTech Harbor, June 2025] Vonova’s Successful Seed Financing for Revolutionary Brain Access Technology | https://neurotechharbor.org/news/venova/
[LinkedIn, retrieved 2024] Vonova | LinkedIn | https://www.linkedin.com/company/vonovaneuro
[Crunchbase, retrieved 2024] Vonova - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/vonova-252d
[ORCID, retrieved 2024] ORCID | https://orcid.org/0000-0001-8837-4506
Articles about Vonova
- Vonova's Catheter Navigates to the Brain Without Drilling the Skull — The San Diego startup, with a neurosurgeon co-founder and a $1 million seed, is targeting chronic subdural hematoma as its first clinical application.